>
Menu
BE
About
The ACS’s mission-driven venture capital fund
Portfolio
Investing in for-profit companies developing novel cancer-focused treatments
Team
Fighting for a world without cancer
News
Contact
Become a Donor
The ACS's mission-driven venture capital fund
BrightEdge exists to accelerate the American Cancer Society's mission for a world without cancer.
About
We invest in the development of life-saving therapeutics
BrightEdge invests in the most promising for-profit oncology companies bringing innovative treatments to market.
Portfolio
Fighting for a World Without Cancer
BrightEdge is led by a world-class team of investors, operators, and entrepreneurs to ensure the best cancer innovations are brought to market.
Team
News
Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers
BrightEdge participates in Auron Therapeutics seed round.
BrightEdge Announces Second Investment in Freenome, Technology Firm Focused on Early Detection for Cancer
BrightEdge Announces Second Investment in Freenome, Technology Firm Focused on Early Detection for Cancer
American Cancer Society’s BrightEdge to Invest in Checkmate Pharmaceuticals
BrightEdge participated in the Series C funding round for Checkmate Pharmaceuticals.
See All News